ThromboGenics Submits Biologics License Application for Ocriplasmin to the FDA

ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA

If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole

Leuven, Belgium - 23 December, 2011 - ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.

The BLA submission, which includes data from two pivotal Phase III trials involving 652 patients in the U.S. and Europe, will undergo a standard review by the FDA. In October 2011, the European Medicines Agency accepted for review ThromboGenics' Marketing Authorisation Application (MAA) for ocriplasmin for the same indication.


Dr Patrik De Haes, ThromboGenics' CEO, said: "Today's submission is a key step towards making ocriplasmin available to the many thousands of patients in the U.S. suffering from a sight-threatening disorder. A standard review by the FDA will allow us to manage our U.S. and European submissions in parallel. In anticipation of these approvals, we are continuing to invest in our commercial organization as we work to build advocacy with the U.S. and international retinal specialist community. With the regulatory dossiers for ocriplasmin now filed, I believe we are making excellent progress towards our goal of becoming a leading biopharmaceutical company focused on addressing unmet needs in ophthalmology."
Symptomatic VMA including macular hole is a progressive condition that if left untreated generally leads to significant visual distortion, deterioration in vision, and in some cases central blindness. Market research conducted by ThromboGenics suggests that there are approximately 500,000 patients annually in the major markets of the EU and the U.S. who could potentially benefit from ocriplasmin.


For further information please contact:
ThromboGenics
Dr. Patrik De Haes, CEO
Chris Buyse, CFO
Tel: + 32 16 75 13 10
[email protected]
Tel: + 32 16 75 13 10
[email protected]

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.